Kureasia

Kureasia is a Tokyo-based biotechnology company dedicated to the discovery and development of novel therapeutics for refractory cancers. Founded in 2019 by industry veterans from Kyowa Kirin, the company focuses on modulating the tumor microenvironment to overcome resistance to existing treatments. Kureasia's pipeline includes small molecule candidates designed to inhibit immunosuppressive pathways and target cancer-associated fibroblasts. Its lead program, KURE-001, is currently in the pre-clinical stage for the treatment of advanced solid tumors. The company leverages a specialized drug discovery platform and strategic collaborations to advance its oncology portfolio toward clinical validation. Kureasia is backed by prominent Japanese venture capital firms, including Fast Track Initiative and JAFCO.